Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.

Pfizer, Takeda and Alphabet-backed degenerative disease drug developer Cortexyme priced its initial public offering in the middle of its range to raise $75m.

Tencent will have to wait a little longer to exit livestreaming platform Douyu, which has decided to delay its initial public offering due to American tariffs on Chinese goods.

Center Laboratories Group and Formosa Laboratories are in line for exits as cancer drug developer Tot Biopharm aims to go public.

Regenerative implant producer OssDsign, based on research at Karolinska University Hospital and Uppsala University, hopes to list on the Nasdaq First North and raise $15.8m.

Meat substitute developer Beyond Meat, which has received backing from two corporate venturers, went public.

SoftBank is mulling the possibility of taking its $98.6bn Vision Fund public and is in talks with Oman over a commitment to a second fund.

The Tencent-backed cosmetic procedure-booking and social media platform floated at the top of its range in a US offering that came after more than $229m of funding.

Pharmstandard, Lung Biotechnology and Posco celebrated exits as the organ transportation system developer went public in a $91m offering.

Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.